| N4BP1 restricts HIV-1 and its inactivation by MALT1 promotes viral reactivation D Yamasoba, K Sato, T Ichinose, T Imamura, L Koepke, S Joas, E Reith, ... Nature Microbiology 4 (9), 1532-1544, 2019 | 71 | 2019 |
| Duration of infectious virus shedding by SARS-CoV-2 Omicron variant–infected vaccinees K Takahashi, M Ishikane, M Ujiie, N Iwamoto, N Okumura, T Sato, ... Emerging infectious diseases 28 (5), 998, 2022 | 66 | 2022 |
| Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants S Miyamoto, T Arashiro, Y Adachi, S Moriyama, H Kinoshita, T Kanno, ... Med 3 (4), 249-261. e4, 2022 | 62 | 2022 |
| Ultrastructure of influenza virus ribonucleoprotein complexes during viral RNA synthesis M Nakano, Y Sugita, N Kodera, S Miyamoto, Y Muramoto, M Wolf, T Noda Communications Biology 4 (1), 858, 2021 | 15 | 2021 |
| National seroepidemiological study of COVID‐19 after the initial rollout of vaccines: Before and at the peak of the Omicron‐dominant period in Japan T Arashiro, S Arai, R Kinoshita, K Otani, S Miyamoto, D Yoneoka, ... Influenza and other respiratory viruses 17 (2), e13094, 2023 | 13 | 2023 |
| Contribution of RNA-RNA interactions mediated by the genome packaging signals for the selective genome packaging of influenza A virus S Miyamoto, Y Muramoto, K Shindo, Y Fujita-Fujiharu, T Morikawa, ... Journal of Virology 96 (6), e01641-21, 2022 | 13* | 2022 |
| Generation of a purely clonal defective interfering influenza virus Y Yamagata, Y Muramoto, S Miyamoto, K Shindo, M Nakano, T Noda Microbiology and immunology 63 (5), 164-171, 2019 | 10 | 2019 |
| In vitro vRNA–vRNA interactions in the H1N1 influenza A virus genome S Miyamoto, T Noda Microbiology and Immunology 64 (3), 202-209, 2020 | 9 | 2020 |
| Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology T Hemmi, A Ainai, T Hashiguchi, M Tobiume, T Kanno, ... Vaccine 40 (41), 5892-5903, 2022 | 7 | 2022 |
| Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA. 4/5 neutralization S Miyamoto, T Arashiro, A Ueno, T Kanno, S Saito, H Katano, S Iida, ... iScience 26 (2), 2023 | 6 | 2023 |
| Migration of influenza virus nucleoprotein into the nucleolus is essential for ribonucleoprotein complex formation S Miyamoto, M Nakano, T Morikawa, A Hirabayashi, R Tamura, ... Mbio 13 (1), e03315-21, 2022 | 6* | 2022 |
| Apple-shaped obesity: A risky soil for cytokine-accelerated severity in COVID-19 T Hosoya, S Oba, Y Komiya, D Kawata, M Kamiya, H Iwai, S Miyamoto, ... Proceedings of the National Academy of Sciences 120 (22), e2300155120, 2023 | 5 | 2023 |
| Propagation of activated B cells by in vitro severe fever with thrombocytopenia syndrome virus infection of human peripheral blood mononuclear cells Y Wada, S Miyamoto, S Iida, K Sano, Y Sato, A Ainai, K Saito, H Katano, ... The Journal of Infectious Diseases 225 (2), 269-281, 2022 | 5 | 2022 |
| Mpox neutralizing antibody response to LC16m8 vaccine in healthy adults E Morino, S Mine, N Tomita, Y Uemura, Y Shimizu, S Saito, T Suzuki, ... NEJM evidence 3 (3), EVIDoa2300290, 2024 | 3 | 2024 |
| Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection S Miyamoto, T Nishiyama, A Ueno, H Park, T Kanno, N Nakamura, ... Proceedings of the National Academy of Sciences 120 (52), e2314808120, 2023 | 3 | 2023 |
| Nasopharyngeal SARS-CoV-2 may not be dispersed by a high-flow nasal cannula T Suzuki, S Morioka, K Yamamoto, S Saito, S Iida, K Teruya, J Takasaki, ... Scientific Reports 13 (1), 2669, 2023 | 3 | 2023 |
| A fatal breakthrough COVID-19 case following bendamustine-rituximab therapy K Kamegai, N Iwamoto, T Togano, K Maeda, Y Takamatsu, Y Miyazato, ... International Journal of Infectious Diseases 121, 85-88, 2022 | 3 | 2022 |
| CP100356 hydrochloride, a P-glycoprotein inhibitor, inhibits Lassa virus entry: implication of a candidate pan-mammarenavirus entry inhibitor T Takenaga, Z Zhang, Y Muramoto, SK Fehling, A Hirabayashi, ... Viruses 13 (9), 1763, 2021 | 3 | 2021 |
| Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval S Miyamoto, Y Kuroda, T Kanno, A Ueno, N Shiwa-Sudo, ... Iscience 26 (5), 2023 | 2* | 2023 |
| Diverse pro-inflammatory ability of mutated spike protein derived from variant strains of SARS-CoV-2 D Kawata, H Iwai, S Oba, Y Komiya, R Koike, S Miyamoto, T Kanno, ... Cytokine 178, 156592, 2024 | | 2024 |
Tadaki SuzukiNational Institute of Infectious DiseasesVerified email at niid.go.jp
